Covering the continuum with standardof-care, innovative, customized, and clinical research options
|
|
- Juniper Andrews
- 5 years ago
- Views:
Transcription
1 Pharma Services Full Service Testing Menu Anatomic Pathology Genomics MultiOmyx Flow Cytometry CDx & IVD Cytogenetics FISH Data Comprehensive testing from one responsive laboratory
2 Covering the continuum with standardof-care, innovative, customized, and clinical research options NeoGenomics has served the oncology and pathology communities for over 13 years. In December 2015, NeoGenomics Laboratories acquired Clarient Diagnostics. With the combined medical and technical expertise of both companies, NeoGenomics has a unique depth of service in hematologic and solid tumor cancer diagnostics. We remain vigilant of patient care and customer service as we continually strive to build a better lab, not just a bigger one. What makes NeoGenomics Pharma Services different from other laboratories? Our service promises, including: We start when you re ready We guarantee you a one-business-day response on project inquiries We will deliver your project data at the highest level Menu Overview NeoGenomics provides one of the largest clinical menus in the world. We add dozens of new tests and testing enhancements each year. If you don t see a test you need, we can develop it. Highlights are: 320+ IHC antibodies 160+ molecular tests 17 liquid biopsy tests 93 FISH probe sets individual probes single genes NeoGenomics also runs a wide variety of clinically validated FDA-approved and FDA-cleared assays that include: Molecular FDA Oncomine Dx Target Test (Tafinlar +Mekinist / dabrafenib+trametinib, Xalkori /crizotinib, Iressa / gefitinib) cobas 4800 BRAF V600 (Zelboraf /vemurafenib) cobas EGFR Mutation Test v2 (Tagrisso /osumertinib, Tarceva /erlotinib) therascreen EGFR RGQ PCR (Gilotrif /afatinib, Iressa /gefitinib) offered as LDT therascreen KRAS RGQ PCR (Erbitux /cetuximab, Vectibix /panitumumab) THxID BRAF (Tafinlar /dabrafenib, Mekinist / trametinib) FISH FDA PathVysion HER-2 (Herceptin /trastuzumab) UroVysion Bladder Cancer Kit Vysis CLL (Venclexta /venetoclax) Vysis ALK (Xalkori /crizotinib) 2 NeoGenomics Laboratories IHC FDA ALK, D5F3 (Xalkori /crizotinib) ER PharmDx Her2/neu Pathway (4B5) PD-L1 SP263 (Imfinzi / durvalumab) HercepTest (Herceptin /trastuzumab) INFORM HER2 Dual ISH (Herceptin /trastuzumab) PD-L1 22C3 PharmDx (Keytruda /pembrolizumab) PD-L PharmDX (Opdivo /nivolumab) PD-L1 SP142 (Tecentriq /atezolizumab) PD-L1 SP263 (Imfinzi /durvalumab) CDx and IVD Development If you don t see a test for your project on our menu, we can help develop an IVD or CDx for your clinical trial. The CDx process works best when development of the test begins before the drug enters clinical trials. Early collaborations between pharmaceutical companies, test manufacturers, and laboratory services can result in faster access to promising new treatments.
3 FISH HemeFISH Acute Lymphocytic Leukemia (ALL) Adult ALL Panel Pediatric ALL Panel Acute Myeloid Leukemia (AML) AML Standard Panel AML Favorable-Risk Panel AML Non-Favorable Risk Panel BCR/ABL1/ASS1 CLL Panel Eosinophilia Panel Lymphoma High-Grade/Large B-Cell Lymphoma Panel Low-Grade/Small B-Cell Lymphoma Panel NHL Panel TCL1 Myelodysplastic Syndrome (MDS) MDS Extended Panel MDS Standard Panel Multiple Myeloma MM/MGUS Panel MM IgH Complex Reflex Panel Plasma Cell Myeloma Prognostic Profile Plasma Cell Myeloma Risk Stratification Profile MPN Panel PML/RARA and RARA Break-Apart X/Y for Engraftment Comprehensive Menu of Individual Hematologic FISH Probes FISH for Solid Tumors 1p/19q Deletion (Glioma) Bladder Cancer FISH BRAF Translocation (Brain & Others) EGFR Amplification (Solid Tumors) HER2 HER2 Breast HER2 Breast Equivocal HER2 Non-Breast Lung Cancer - NSCLC ALK RET ROS1 MET (Solid Tumors) MYCN Amplification (Solid Tumors) NeoSITE B.E. (Barrett s Esophagus) NeoSITE Cervical NeoSITE Melanoma PDGFRA Amplification (Brain) PTEN (Prostate & Others) RET (Solid Tumors) Sarcoma DDIT3 (CHOP) EWSR1 MDM2 SS18 (SYT) TOP2A (Breast) X/Y for Molar Pregnancy *All probes available individually Flow Cytometry Comprehensive Leukemia/Lymphoma Analysis CD4/CD8 Ratio for BAL DNA Ploidy/Cell Cycle Analysis Follow-Up and Add-On Panels Plasma Cell Panel PNH High Sensitivity Evaluation T&B Tissue Panel T-Cell Therapy Panel V-Beta T-Cell Clonality ZAP-70 Lymphoid Panel NeoGenomics Laboratories 3
4 Histology Digital Image Analysis In Situ Hybridization (ISH) CMV EBER HER2 Dual ISH HPV RNA ISH Kappa/Lambda Special Stains AcP AFB Alcian Blue Calcium Stain Chloroacetate Esterase Colloidal Iron Congo Red Copper Stain Elastic Stain Fite Stain Fontana Masson Giemsa GMS Gram Stain Hall Bile Stain Iron MPO Cytochemical Stain Mucicarmine Naphthol Acetate Esterase ± sodium fluoride inhibition Naphthol Butyrate Esterase PAS PAS for Fungus PAS with Digestion Reticulin TRAP Cytochemical Trichrome Warthin Starry Wright Giemsa Immunohistochemistry (IHC) Antibodies AACT AAT ACTH Adenovirus AFP ALK (D5F3) ALK-1 (heme) Amyloid A Amyloid P Annexin A1 AR Ariginase 1 ATRX B72.3 BCA-225 BCL1/Cyclin D1 BCL2 BCL6 BerEP4 Beta Catenin BG8 BOB1 BRAF V600E BRCA1 Breast Triple Stain (CK5 + p63 + CK 8/18) CA125 CA19.9 Calcitonin Caldesmon Calponin Calretinin CAM 5.2 (CK LMW) Carbonic Anhydrase IX (CA IX) Cat Scratch Cathepsin D CD1a CD2 CD3 CD4 CD5 CD7 CD8 CD10 CD11c CD14 CD15 CD19 CD20 CD21 CD22 CD23 CD25 CD30 CD31 CD33 CD34 CD35 CD38 CD42b CD43 CD44 CD45 (LCA) CD45RB CD45RO CD56 CD57 CD61 CD68 CD71 CD79a CD99 CD117 ckit CD123 CD138 CD163 CDK4 CDX2 CDX2/CK7 Double Stain CEA (Mono) CEA (Poly) Chromogranin A CK 5/6 CK 7 CK 10/13 CK 14 CK 17 CK 18 CK 19 CK 20 CK AE1/AE3 CK HMW (CK903/34BE12) CK HMW +p63 CK HMW/LMW Double Stain CK OSCAR cmet CMV cmyc 4 NeoGenomics Laboratories
5 Collagen IV COX2 crel CXCR4 D240 DBA.44 Desmin DOG1 DPC4 EBV (LMP1) E-Cadherin Eg5 EGFR EGFR (E746-A750del specific) EGFR (L858R mutant specific) elf4e EMA ER ERCC1 ERG Factor VIII RA Factor XIIIa Fascin Fli-1 FOXP1 FOXP3 FSH Galectin 3 Gastrin GATA3 GCDFP15 GCET1 GFAP GH Glucagon GLUT1 Glycophorin A Glypican-3 Granzyme B GST Pi H. Pylori HBME1 HCG Beta Hemoglobin A Hepatitis B Core Antigen Hepatitis B Surface Antigen HepPar1 HER2 Breast HER2 Non-Breast HGAL HHV8 HLA-DR HMB45 HPL HPV HSV I HSV I/II HSV II IDH1 IgA IgD IgG IgG4 IgM Inhibin inos Insulin Kappa Ki67 Ki67/Caspase 3 (Double Stain) Lambda Laminin Langerin LEF1 LH LMO2 Lysozyme MAL Mammaglobin MDM2 Melan A (Mart1) Mesothelin MGMT MITF MLH1 MOC31 MPO MSA MSH2 MSH6 MUC1 MUC2 MUC4 MUC5 MUC6 MUM1 MyoD1 Myogenin Myoglobin Napsin A NeuN NF (Neurofilament) NKX2.2 NKX3.1 NSE OCT2 OCT4 Olig2 p16 p21 p27 p40 NeoGenomics Laboratories 5
6 IHC Antibodies (Continued) p53 p57 p63 p120 Catenin P501S P504S pakt Pan Melanoma (S100 + Melan A + Tyrosinase) Pancreatic Polypeptide (PP) Pan-Cytokeratin Plus (AE1/AE3 + CK8/18) Pan-Keratin (AE1/AE3/PCK26) Pan-Melanoma/Ki67 Parafibromin Parvovirus PAX2 PAX5 PAX8 PD1 PD-L FDA (OPDIVO ) PD-L1 SP142 FDA (TECENTRIQ ) PD-L1 SP263 (IMFINZI ) PD-L1, 22C3 FDA (KEYTRUDA ) Perforin perk PgR phistone H3 (PHH3) PLAP PMS2 Pneumocystis Carinii (Jiroveci) Prealbumin (TTR) Prolactin Prostate Triple Stain PSA PSAP/HPAP PSMA PTEN PTH PU.1 RCC1 Retinoblastoma Protein (RB) ROS1 RRM1 S100 S100p SALL4 SATB2 Serotonin SF1 SMA SMMHC Smoothelin Somatostatin Somatostatin Receptor, Type 2 SOX2 SOX10 SOX11 Spirochete STAT6 Surfactant Survivin SV40 Synaptophysin Tau TCL1 TCR BetaF1 TdT TFE3 TGF Alpha Thrombomodulin (TM) Thyroglobulin (TGB) TIA1 TLE1 TOPO1 Toxoplasma TRAcP Tryptase TS TSH TTF1 Tuberculosis Tyrosinase Uroplakin II Uroplakin III Varicella Zoster Virus (VZV) VEGF Villin Vimentin WT1 ZAP70 6 NeoGenomics Laboratories
7 Molecular Testing Hematologic Cancer Panels & Profiles NeoTYPE Cancer Profiles Myeloid Disorders (54 genes) Disease-Specific (7 options) BTK Inhibitor Acquired Resistance Panel BTK Inhibitor Primary Susceptibility Panel Chimerism/DNA Fingerprinting MPN Extended Reflex Panel MPN Standard Reflex Panel NeoARRAY SNP/Cytogenetic Profile Immuno-Oncology Microsatellite Instability (MSI) Mismatch Repair IHC (MMR) PD-L1 IHC Tumor Mutation Burden Specialty Tests HPV DNA Tissue Testing NanoString Pan Cancer Immune Profiling Panel (770 genes) Universal Fusion/Expression Profile (1385 genes) Solid Tumor Cancer Panels & Profiles NeoTYPE Cancer Profiles Discovery (315 genes) Precision (48 genes) Tumor-Specific (18 options) NeoLAB Liquid Biopsies Hematologic Cancers AML Profile BTK Inhibitor Acquired Resistance Panel MDS/CMML Profile *Custom assays available Myeloid Disorders Profile ALK/RET/ROS1 Fusion Profile FLT3 ALK/NTRK/RET/ROS1 Fusion Profile Microsatellite Instability IDH1/IDH2 inv(16), CBFB-MYH11 Translocation NeoARRAY SNP/Cytogenetic Profile KIT (c-kit) NGS Comprehensive Sarcoma Fusion Profile KRAS NGS Ewing Sarcoma Fusion Profile NPM1 NRAS NGS Non-Ewing Sarcoma Fusion Profile NGS Rhabdomyosarcoma Fusion Profile NGS Pediatric Sarcoma Fusion Profile NGS Pediatric Sarcoma Fusion Profile NGS Thyroid Fusion Profile RAS/RAF Panel PML-RARA Translocation, t(15;17) RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21) NeoLAB Liquid Biopsies Solid Tumor EGFR T790M Prostate Solid Tumor Monitor (48 genes) Hereditary Cancer Predisposition BRCA1/2 Cancer Susceptibility for Peds Comprehensive Panel (73 genes) DNA Repair Panel EGFR T790M Germline Mutation HOXB13 Genotyping (Prostate) Inherited Bone Marrow Failure Panel (58 genes) Lynch Syndrome (5 genes) NeoGenomics Laboratories 7
8 Our Differentiators Expertise, Flexibility, Scalability Rapid Project Start-Up Dedicated Project Scientists Extensive Menu Custom Assay Design Platform Agnostic New tests are added frequently. See our website for the most current and complete listing. NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories. Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information. neogenomics.com 2017 NeoGenomics Laboratories, Inc. All Rights Reserved. All other trademarks are the property of their respective owners. Rev Commonwealth Dr., Suite 9 Fort Myers, FL United States Phone: Fax: Columbia Aliso Viejo, CA United States Phone: Fax: West Bellfort St., Suite 2001 Houston, TX United States Phone: / Fax: A-One Business Center Bâtiment A5, 2nd Floor Z.A. La Pièce/Route de l Etraz Rolle, Switzerland Phone: +41 (0) Fax: +41 (0)
Molecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.
Molecular Oncology & Pathology Hereditary Cancer Somatic Cancer Liquid Biopsy Next-Gen Sequencing qpcr Sanger Sequencing Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine
More informationOut-Patient Billing CPT Codes
Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK UCL-Advanced Diagnostics 1st Floor, Rockefeller Building 21 University Street London WC1E 6JJ Contact: David Allen Tel: +44 (0)20 7679 6912
More informationAugust 17, Dear Valued Client:
August 7, 08 Re: CMS Announces 6-Month Period of Enforcement Discretion for Laboratory Date of Service Exception Policy Under the Medicare Clinical Laboratory Fee Schedule (the 4 Day Rule ) Dear Valued
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles 30+ Multimethod Assays for Hematologic Diseases and Solid Tumors Molecular FISH Anatomic Pathology The next generation of diagnostic, prognostic, and therapeutic assessment What
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles Multimethod Analysis of 25+ Hematologic Diseases and Solid Tumors Anatomic Pathology FISH Molecular The next generation of diagnostic, prognostic, and therapeutic assessment NeoTYPE
More informationNEW IHC A n t i b o d i e s
NEW IHC Antibodies TABLE OF CONTENTS NEW IHC ANTIBODIES from Cell Marque CITED1 (5H6).... 1 Claudin 7 (5D10F3).... 1 GATA1 (4F5).... 1 Transgelin (2A10C2).... 1 NEW IHC ANTIBODIES using RabMAb Technology
More informationantibodies by application
antibodies by application Higher Affinity Higher Sensitivity Higher Specificity A selection of Over 460 Rabbit and Mouse Monoclonal For Use in Clinical and Research Applications Bio SB s RBT & MMab s BSB
More informationBreast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2 on all newly diagnosed cases
Adrenal cortical carcinoma Inhibin Synap Melan-A Calretinin Vimentin Chromogr CK7 CK20 Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationTEST MENU BY SPECIALTY
1 TEST MENU BY SPECIALTY Breast Pathology Surgical excisions, needle core biopsies, and plastic surgery accepted from all sites Assessment of margins Axillary lymph node dissections Sentinel lymph nodes
More information2016 Antibodies by Application
2016 by Application Higher Affinity Higher Sensitivity Higher Specificity New Rabbit Monoclonal ALK, EP301 Amyloid A, EP335 B7H3/CD276, RBT B7H3 bcl6, EP278 BRAF V600E, RM8 C4d, EP273 CD5, RED1 CD8, EP334
More informationProtocols for Zytomed Systems antibodies on fully automated IHC staining systems date of issue: September 20, 2012
Protocols for Zytomed Systems antibodies on fully automated IHC staining systems date of issue: September 20, 2012 These protocols were provided by customers. Under no circumstances shall Zytomed Systems
More informationHSL-Advanced Diagnostics 2018 / 19 Test & Service List
HSL-Advanced Diagnostics 2018 / 19 Test & Service List 2018/19 TEST & SERVICE LIST Haematoxylin & Eosin H&E H&E per slide Routine Immunohistochemistry Immunohistochemical demonstration of an antigen in
More informationIHC Panels as an Aid in Diagnostic Decision Making
IHC Antibody Test Selection Using a Panel Approach Steven Westra B.S. Reagent Product Specialist Leica Biosystems IHC Panels as an Aid in Diagnostic Decision Making Diagnostic Use of Tumors Using Algorithms
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Christie Hospital Manchester M20 4BX Contact: Neil Wrathall Tel: +44 (0) 161 918 7264 Fax: +44 (0) 161 446 8549 E-Mail: neil.wrathall@christie.nhs.uk
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Schedule of ccreditation United Kingdom ccreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK External Quality ssessment Services for Cancer Diagnostics CIC Issue No: 005
More informationGENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)
CANCER (NSCLC) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are
More informationTEST MENU
CISH EBV (EBER1 RNA) EBVISH 88365 CISH Kappa by ISH 88365 or 88364 CISH Lambda by ISH 88365 or 88364 Cytogenetics Chromosomal Analysis Cytogenetics 88237, 88264, 88280, 88291 (may include 88285 or additional
More informationYour single-source laboratory solution. FISH Probe Library
Your single-source laboratory solution. FISH Probe Library Alphabetical List by Probe with Clinical Indication Probe Clinical Indication 1p36 (TP73)/19q13 (GLTSCR) 1q21 (CKS1B) 5q (CSF1R/RPS14) 7q (MDFIC)
More informationI. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
More informationReady-to-use, CE-IVD antibodies for pathology
A-1-Antichymotrypsin A-1-Antitrypsin Abcc3 Aberrant Endothelial 4A11 Cell ACTH BSB-25; AH26 Actin 1A4 Actin, Muscle Specific HHF35 Actin, Smooth Muscle BSB-15 (ASM/H12) Adenovirus 20/11 and 2/6; A62020069A
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationTEST MENU
1p36/19q13 - Oligodendroglioma Oligodendroglioma Panel test (1p36/1q25 and 19q13/19p13) 88374x2 1q21+1p21 Myeloma Panel test 88374 7q31 / del 7q 7q31/CEP7 88374 11q22.3 (ATM) CLL/SLL panel test 88374 11q23
More informationTEST MENU
1p36/19q13 - Oligodendroglioma Oligodendroglioma Panel test (1p36/1q25 and 19q13/19p13) 88374x2 1q21+1p21 Myeloma Panel test 88374 7q31 / del 7q 7q31/CEP7 88374 11q22.3 (ATM) CLL/SLL panel test 88374 11q23
More informationIn Situ Hybridization Immunohistochemistry
2013-2014 In Situ Hybridization Immunohistochemistry A History of Delivering Superior Products Genemed Biotechnologies, Inc. was founded in 1987 and is located in the center of the South San Francisco
More informationUtility of liquid biopsies EQA Program Naples, IT Sidney A. Scudder, MD Director, Clinical Science 13 May, 2017
Utility of liquid biopsies EQA Program Naples, IT Sidney A. Scudder, MD Director, Clinical Science 13 May, 2017 picture placeholder Agenda cobas EGFR Mutation Test v2 Ring Trial SQI Semi Quantitative Index
More informationPatient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017
Patient Leader Education Summit Precision Medicine: Today and Tomorrow March 31, 2017 Precision Medicine: Presentation Outline Agenda What is a Precision Medicine What is its clinical value Overview of
More informationImplementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges
Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges Frédérique Nowak - 21 october 2015 "Putting Science into Standards event:
More informationCleveland Clinic Laboratories
Cleveland Clinic Laboratories Anatomic Pathology Special s Group I for Microorganisms Special s Group I 88312 Fite stain Gomori s methenamine silver (GMS) Gram Gridley PAS/light green counterstain Warthin-Starry
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK 05/09/2018 Cellular Pathology Level 2 Esher Wing Galsworthy Road Kingston upon Thames KT2 7QB Contact: Dr Sussan Gharaie Tel: +44 (0)208 934
More informationDifferential diagnosis of HCC
Hepatocellular Carcinoma Quest for an Ideal Immunohistochemical Panel Sanjay Kakar, MD UCSF Differential diagnosis of HCC Hepatocellular lesions Adenoma, FNH, HG dysplasia Adenocarcinoma CholangioCA, metastasis
More informationCurrent and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian
Current and future applications of Molecular Pathology Kathy Walsh Clinical Scientist NHS Lothian Molecular Pathology in Solid tumours Cancer type Genes tested Purpose Associated treatments Non small cell
More informationmolecular oncology services
Molecular Oncology molecular oncology services ATIENTS.ANSWERS.RESULTS. www.aruplab.com/oncology MARCH 2018 Information in this brochure is current as of March 2018. All content is subject to change. lease
More informationCleveland Clinic Laboratories
Cleveland Clinic Laboratories Anatomic Pathology Special Stains Group I for Microorganisms Special Stains Group I 88312 Fite stain Gomori s methenamine silver (GMS) Gram PAS/light green counterstain Warthin-Starry
More informationRegulatory Landscape for Precision Medicine
Regulatory Landscape for Precision Medicine Adam C. Berger, Ph.D. Office of In Vitro Diagnostics and Radiological Health, FDA FOCR-Alexandria A Blueprint for Breakthrough Meeting September 13, 2017 1 What
More informationComprehensive genomic profiling for various solid tumors
Content Highlight Test Specification Test Content Performance Validation Test Report I II III IV V The NovoPM TM comprehensive cancer genomic profiling test Comprehensive genomic profiling for various
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Cellular Pathology Laboratory Contact: Breege Nicholson Queen Elizabeth Hospital Tel: +44 (0) 208 333 3000 ext. 8478 Stadium Road E-Mail:
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationReview of NEO Testing Platforms. Lawrence M. Weiss, MD Medical Director, Aliso Viejo
Review of NEO Testing Platforms Lawrence M. Weiss, MD Medical Director, Aliso Viejo Lawrence Weiss, M.D. Medical Director, Aliso Viejo Dr. Weiss currently serves as NeoGenomics Medical Director, Aliso
More informationPediatric Oncology & Pathology Services
Pediatric Oncology & Pathology Services Anatomic Pathology Flow Cytometry Cytogenetics Pharma Services Diagnostic, Prognostic, Predictive, and Predisposition Testing Pediatric Oncology & Pathology Services
More informationInnovation, Uncertainty and Reimbursement Processes in Precision Medicine: The Case of PD-L1
Innovation, Uncertainty and Reimbursement Processes in Precision Medicine: The Case of PD-L1 Monday, October 17, 2016 MaRS Discovery District, Toronto This session was generously sponsored by Merck Canada
More informationPantoprazole icd 10 code
Pantoprazole icd 10 code in persons with recurrent or metastatic non-small cell lung cancer who are being considered for treatment with dabrafenib (Tafinlar), pembrolizumab (Keytruda), or vemurafenib (Zelboraf);
More informationPersonalised Healthcare. will it deliver? Bob Holland Head of Personalised Healthcare & Biomarkers Innovative Medicines AstraZeneca R&D
Personalised Healthcare x will it deliver? Bob Holland Head of Personalised Healthcare & Biomarkers Innovative Medicines AstraZeneca R&D Personalised Healthcare It is delivering! Bob Holland Head of Personalised
More informationThe role of immunohistochemistry in surgical pathology of the uterine corpus and cervix
The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
More informationCost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic
Cost-Effective Strategies in the Workup of Hematologic Neoplasm Karl S. Theil, Claudiu V. Cotta Cleveland Clinic In the past 12 months, we have not had a significant financial interest or other relationship
More informationSelect analysis on the next pages. Sample request and sending address see last page. Institut für Pathologie und Molekularpathologie
Diagnostic Tumor Genome Analysis Schmelzbergstrasse 12 8091 Zürich Tel.: (+41) 044 255 3929 Fax.: (+41) 044 255 4416 Client (address, telephone number): ngs.pathologie@usz.ch www.pathologie.usz.ch Sample-Nr:
More informationADVANCED STAINING PRODUCT CATALOG. In Situ Hybridization Probes Immunohistochemistry Antibodies Detection Systems Ancillary Reagents
2017 ADVANCED STAINING PRODUCT CATALOG In Situ Hybridization Probes Immunohistochemistry Antibodies Detection Systems Ancillary Reagents A History of Delivering Superior Products Genemed a wholly-owned
More informationImmunohistochemistry. Potential and challenges To be or not to be
Immunohistochemistry Potential and challenges To be or not to be Søren Nielsen Scheme Manager NordiQC Aalborg University Hospital, Denmark Vårmöte 19.05.2016 Karlstad Overview IHC project coordinator at
More informationTEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days
TEST MENU CANCER/LEUKEMIA CHROMOSOME ANALYSIS Chromosome Analysis Bone Marrow 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Bone Marrow Core 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome
More informationTechnology from Abcam
CD2 (EP222) CD2 is one of the earliest T-cell lineage restricted antigens to appear during T-cell differentiation and only rare CD2+ cells can be found in the bone marrow. Anti-CD2 is a pan-t-cell antigen
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service High Street, Feltham, Middlesex, TW13 4UN, UK
21-47 High Street, Feltham, Middlesex, TW13 4UN, UK Cellular Pathology Pathology Department Northampton General Hospital Cliftonville Northampton Northamptonshire NN1 5BD Contact: Mary Pendleton Tel: +44
More informationDiagnostic test Suggested website label Description Hospitals available
Diagnostic test Suggested website label Description Hospitals available Abbott Molecular Inc, PATHVYSION HER-2 DNA Probe Kit (FISH) PathVysion kit A diagnostic tool used to determine whether a particular
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationThe Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation
The Panel Approach to Diagnostics Lauren Hopson International Product Specialist Cell Marque Corporation Cell Marque Rocklin, California About Cell Marque: IVD primary antibody manufacturer Distributors
More informationThe clinically challenging entity of liver metastasis from tumors of unknown primary
The clinically challenging entity of liver metastasis from tumors of unknown primary Xuchen Zhang, MD, PhD Associate Professor of Pathology Department of Pathology Yale University School of Medicine Liver
More informationThe new Leeds Solid Tumour Molecular Oncology Diagnostics Service. Paul Roberts, Genetics, Leeds
The new Leeds Solid Tumour Molecular Oncology Diagnostics Service Paul Roberts, Genetics, Leeds Molecular Oncology services pre-2013 DNA lab Germline cancer Cytogenetics lab FISH, cell culture, molecular
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationMolecular Diagnostics Overview JAN A. NOWAK, PHD, MD PATHOLOGY AND LABORATORY MEDICINE MOLECULAR DIAGNOSTICS LABORATORY FEBRUARY 15, 2018
Molecular Diagnostics Overview JAN A. NOWAK, PHD, MD PATHOLOGY AND LABORATORY MEDICINE MOLECULAR DIAGNOSTICS LABORATORY FEBRUARY 15, 2018 Some Key Points Molecular Testing has applications in every section
More informationHEMATOPATHOLOGY DIAGNOSIS & SUBTYPING. Use of IHC. Use of Polymerase Chain Reaction (PCR) Use of Flow Cytometry
HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING The 2008 WHO classification system for tumors of hematopoietic and lymphoid tissues specifies that various combinations of immunophenotypic
More informationBlastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )
Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH2017-0314) Habibe Kurt, Joseph D. Khoury, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Guilin Tang, L. Jeffrey Medeiros, and
More informationComprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.
Comprehensive Genomic Profiling, in record time Accurate. ly Proven. Fast. PCDx advantages Comprehensive genomic profiling, in record time PCDx Comprehensive Genomic Profiling (CGP) provides precise information
More informationCompanion Diagnostics: Technologies and Markets. Robert Hunter. March Report Code: BIO077C
Companion Diagnostics: Technologies and Markets March 2017 Robert Hunter Report Code: BIO077C Table of Contents Chapter 1: Introduction... 1 Study Goals and Objectives... 1 Reasons for Doing the Study...
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Department of Cellular Pathology Forth Valley Royal Hospital Stirling Road Larbert FK5 4WR Contact: Suzanne Ferra Tel: 01324 566643 Tel: +44
More informationTargeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Issue No: 002 Issue date: 05 March 2018 Berkshire and Surrey Pathology Services Department of Histopathology Wexham Park Hospital Slough Berkshire
More informationLearning from the Impact of the Drug-Diagnostics Strategy in Oncology
Learning from the Impact of the Drug-Diagnostics Strategy in Oncology Critical Path to TB Drug Regimens 2017 Workshop Washington DC March 22, 2017 Jan Trøst Jørgensen, M.Sc.Pharm., Ph.D. Dx-Rx Institute
More informationHistopathological diagnosis of CUP
Histopathological diagnosis of CUP Dr Karin Oien karin.oien@glasgow.ac.uk Disclosure slide Dr Karin Oien has no financial interests in any company mentioned in this presentation. Dr Karin Oien is conducting
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationCurrent Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors)
Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors) Kael Mikesell, DO McKay-Dee Hospital May 14, 2015 Outline Update to DNA Testing
More informationReporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota
Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota Reporting cytogenetics What is it? Terminology Clinical value What details are important Diagnostic Tools for Leukemia
More informationGiorgio V. Scagliotti Università di Torino Dipartimento di Oncologia
Giorgio V. Scagliotti Università di Torino Dipartimento di Oncologia giorgio.scagliotti@unito.it Politi K & Herbst R. Clin. Cancer Res. 2015; 21:2213 Breast Colorectal Gastric/GE Junction Tumor Type Head
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda
More informationIMMUNOPROFILES OF THE MAJOR RENAL NEOPLASMS (%staining)
Stain Clear Cell Papillary IMMUNOPROFILES OF THE MAJOR RENAL NEOPLASMS (%staining) Chromophobe Collecting Duct Carcinom a Sarcomatoid Xp11 Translocat ion Dr Jon Oxley See also www.jonoxley.com Page 1 MTSCC
More informationRole of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney
Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor
More informationPredictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities
Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Sujana Movva 1, Wenhsiang Wen 2, Wangjuh Chen 2, Sherri Z. Millis 2, Margaret von Mehren 1, Zoran
More informationPersonalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients
Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK operating as North East Essex and Suffolk Pathology Service (NEESPS) Cellular Pathology Contact: Lynn Partridge Ipswich Hospital Tel: +44
More informationProducts for Molecular Pathology
Products for Molecular Pathology At Bio SB our passion is providing biomedical laboratories with the tools to improve the diagnosis, prognosis and therapies that benefit patients worldwide. Bio SB is proud
More informationCharles Halsey, DVM, PhD, DACVP Pfizer, Inc. IHC Resources
Charles Halsey, DVM, PhD, DACVP Pfizer, Inc. IHC Resources 1 IHC Identification Targets Specimens Controls 2 Tissue controls Trouble Spots 3 The Key to Description IHC Description 4 Intermediate Filaments
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Paediatric Histopathology Western Bank Sheffield S10 2TH United Kingdom Contact: Tel: +44 (0) 1142 717240 Fax: +44 (0) 1142 706121 E-Mail:
More informationNGS IN ONCOLOGY: FDA S PERSPECTIVE
NGS IN ONCOLOGY: FDA S PERSPECTIVE ASQ Biomed/Biotech SIG Event April 26, 2018 Gaithersburg, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration (FDA) Center for
More informationKeytruda (pembrolizumab)
Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The
More informationUCL-Advanced Diagnostics. 2015/16 Service Update
UCL-Advanced Diagnostics 2015/16 Service Update About UCL-Advanced Diagnostics UCL Advanced Diagnostics (UCL-AD) is the immunohistochemistry, in situ and molecular diagnostics service arm of the UCL-Cancer
More informationLUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
More informationNGS ONCOPANELS: FDA S PERSPECTIVE
NGS ONCOPANELS: FDA S PERSPECTIVE CBA Workshop: Biomarker and Application in Drug Development August 11, 2018 Rockville, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration
More informationCutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement
Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchcock Medical Center
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Cellular Pathology Contact: Dr Nicola Chaston East Kent Hospitals University Tel: +44 (0)1233 616183 NHS Foundation Trust Fax: +44 (0) 01233
More informationYour single-source laboratory solution. Antibody Library
Your single-source laboratory solution. Antibody Library A-ACT Alpha-1 antichymotrypsin; histiocytes; pancreatic pseudopapillary tumor A-AT Alpha-1-antitrypsin; inherited AAT deficiency ACTH Adrenocorticotropic
More informationDisclosure of Relevant Financial Relationships NON-SMALL CELL LUNG CANCER: 70% PRESENT IN ADVANCED STAGE
MORPHOLOGY AND MOLECULAR TESTING IN NON-SMALL CELL OF LUNG NEW FRONTIEIRS IN CYTOPATHOLOGY PRACTICE American Society for Cytopathology San Antonio, Texas Sunday March 5, 2017 Disclosure of Relevant Financial
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationQIAGEN Complete Solutions for Liquid Biopsy Molecular Testing
QIAGEN Complete Solutions for Liquid Biopsy Molecular Testing Christopher Swagell, PhD Market Development Manager, Advanced Molecular Pathology QIAGEN 1 Agenda QIAGEN Solid Tumor Testing and Liquid Biopsy
More informationTARGETED THERAPY FOR LUNG CANCER. Patient and Caregiver Guide
TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Why Targeted Therapy?...2 Lung Cancer Basics...2 Changes in
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationMolecular Diagnosis. Nucleic acid based testing in Oncology
Molecular Diagnosis Nucleic acid based testing in Oncology Objectives Describe uses of NAT in Oncology Diagnosis, Prediction, monitoring. Genetics Screening, presymptomatic testing, diagnostic testing,
More informationDiagnostic & Predictive Immunohistochemistry in Lung Carcinomas
Diagnostic & Predictive Immunohistochemistry in Lung Carcinomas Lynette M. Sholl, M.D. Associate Pathologist, Brigham and Women s Hospital Associate Professor, Harvard Medical School Boston, MA Disclosures
More informationNucleic Acid Testing - Oncology. Molecular Diagnosis. Gain/Loss of Nucleic Acid. Objectives. MYCN and Neuroblastoma. Molecular Diagnosis
Nucleic Acid Testing - Oncology Molecular Diagnosis Nucleic acid based testing in Oncology Gross alterations in DNA content of tumors (ploidy) Gain/Loss of nucleic acids Markers of Clonality Oncogene/Tumor
More informationMethods used to diagnose lymphomas
Institut für Pathologie Institut für Pathologie Methods used to diagnose lymphomas Prof. Dr.Med. Leticia Quintanilla-Fend Molecular techniques NGS histology Cytology AS-PCR Sanger seq. MYC Immunohistochemistry
More informationTumores de células pequeñas, redondas y azules: diagnóstico diferencial cuando el tiempo apremia
Tumores de células pequeñas, redondas y azules: diagnóstico diferencial cuando el tiempo apremia Sílvia Bagué Servei de Patologia Hospital de Sant Pau Barcelona Soft tissue sarcomas Heterogeneous group
More information